Processa Pharmaceuticals (PCSA) 10-Q 30 Oct 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Oct. 15, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-39531
Entity Registrant Name	Processa Pharmaceuticals, Inc.
Entity Central Index Key	0001533743
Entity Tax Identification Number	45-1539785
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7380 Coca Cola Drive
Entity Address, Address Line Two	Suite 106
Entity Address, City or Town	Hanover
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21076
City Area Code	443
Local Phone Number	776-3133
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	PCSA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,266,944

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 2,891,464	$ 4,706,197
Prepaid expenses and other	1,946,675	926,300
Total Current Assets	4,838,139	5,632,497
Property and Equipment, net	5,317	2,554
Other Assets
Lease right-of-use assets, net of accumulated amortization	93,161	146,057
Security deposit	5,535	5,535
Total Other Assets	98,696	151,592
Total Assets	4,942,152	5,786,643
Current Liabilities
Current maturities of lease liabilities	94,676	83,649
Accounts payable	711,710	311,617
Due to licensor		189,000
Due to related parties		39
Accrued expenses	412,813	146,274
Total Current Liabilities	1,219,199	730,579
Non-current Liabilities
Non-current lease liabilities	2,168	66,905
Total Liabilities	1,221,367	797,484
Commitments and Contingencies
Stockholders’ Equity
Common stock, par value $0.0001, 100,000,000 shares authorized: 3,271,944 issued and 3,266,944 outstanding at September 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023	327	129
Additional paid-in capital	88,510,949	80,658,111
Treasury stock at cost — 5,000 shares at September 30, 2024 and December 31, 2023	(300,000)	(300,000)
Accumulated deficit	(84,490,491)	(75,369,081)
Total Stockholders’ Equity	3,720,785	4,989,159
Total Liabilities and Stockholders’ Equity	$ 4,942,152	$ 5,786,643

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	3,271,944	1,291,000
Common stock, shares outstanding	3,266,944	1,286,000
Treasury stock shares	5,000	5,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating Expenses
Research and development	$ 2,287,525	$ 1,151,740	$ 5,556,694	$ 4,478,793
General and administrative	1,137,328	1,015,872	3,759,781	4,508,818
Operating Loss	(3,424,853)	(2,167,612)	(9,316,475)	(8,987,611)
Other Income (Expense)
Interest income, net	40,150	85,661	195,065	271,022
Net Loss	$ (3,384,703)	$ (2,081,951)	$ (9,121,410)	$ (8,716,589)
Net Loss per Common Share - Basic	$ (1.03)	$ (1.54)	$ (3.13)	$ (6.81)
Net Loss per Common Share - Diluted	$ (1.03)	$ (1.54)	$ (3.13)	$ (6.81)
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic	3,275,998	1,350,188	2,909,941	1,279,298
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Diluted	3,275,998	1,350,188	2,909,941	1,279,298

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 80	$ 72,018,222	$ (300,000)	$ (64,247,561)	$ 7,470,741
Balance. shares at Dec. 31, 2022	806,774		(5,000)
Stock-based compensation	$ 1	341,503			341,504
Stock-based compensation, shares	3,195
Shares issued in connection with capital raise, net of transaction costs	$ 42	6,352,035			6,352,077
Shares issued in connection with capital raise, net of transaction costs, shares	421,611
Net loss				(4,022,073)	(4,022,073)
Balance at Mar. 31, 2023	$ 123	78,711,760	$ (300,000)	(68,269,634)	10,142,249
Balance. shares at Mar. 31, 2023	1,231,580		(5,000)
Balance at Dec. 31, 2022	$ 80	72,018,222	$ (300,000)	(64,247,561)	7,470,741
Balance. shares at Dec. 31, 2022	806,774		(5,000)
Net loss					(8,716,589)
Balance at Sep. 30, 2023	$ 124	80,431,905	$ (300,000)	(72,964,150)	7,167,879
Balance. shares at Sep. 30, 2023	1,236,580		(5,000)
Balance at Mar. 31, 2023	$ 123	78,711,760	$ (300,000)	(68,269,634)	10,142,249
Balance. shares at Mar. 31, 2023	1,231,580		(5,000)
Stock-based compensation		319,123			319,123
Net loss				(2,612,565)	(2,612,565)
Warrant granted in connection with a consulting agreement		1,310,875			1,310,875
Balance at Jun. 30, 2023	$ 123	80,341,758	$ (300,000)	(70,882,199)	9,159,682
Balance. shares at Jun. 30, 2023	1,231,580		(5,000)
Net loss				(2,081,951)	(2,081,951)
Stock-based compensation, net of forfeitures	$ 1	142,893			142,894
Stock-based compensation, net of forfeitures, shares	5,000
Settlement of stock award		(52,746)			(52,746)
Balance at Sep. 30, 2023	$ 124	80,431,905	$ (300,000)	(72,964,150)	7,167,879
Balance. shares at Sep. 30, 2023	1,236,580		(5,000)
Balance at Dec. 31, 2023	$ 129	80,658,111	$ (300,000)	(75,369,081)	4,989,159
Balance. shares at Dec. 31, 2023	1,291,000		(5,000)
Stock-based compensation	$ 1	167,642			167,643
Stock-based compensation, shares	13,176
Shares issued in connection with capital raise, net of transaction costs	$ 156	6,282,274			6,282,430
Shares issued in connection with capital raise, net of transaction costs, shares	1,555,555
Net loss				(2,726,381)	(2,726,381)
Settlement of stock award		(8,561)			(8,561)
Shares issued in connection with license agreement	$ 1	188,999			189,000
Shares issued in connection with license agreement, shares	5,000
Shares withheld to pay income taxes on stock-based compensation	$ (1)	(9,923)			(9,924)
Shares withheld to pay income taxes on stock-based compensation, shares	(3,750)
Balance at Mar. 31, 2024	$ 286	87,278,542	$ (300,000)	(78,095,462)	8,883,366
Balance. shares at Mar. 31, 2024	2,860,981		(5,000)
Balance at Dec. 31, 2023	$ 129	80,658,111	$ (300,000)	(75,369,081)	4,989,159
Balance. shares at Dec. 31, 2023	1,291,000		(5,000)
Net loss					(9,121,410)
Balance at Sep. 30, 2024	$ 327	88,510,949	$ (300,000)	(84,490,491)	3,720,785
Balance. shares at Sep. 30, 2024	3,271,944		(5,000)
Balance at Mar. 31, 2024	$ 286	87,278,542	$ (300,000)	(78,095,462)	8,883,366
Balance. shares at Mar. 31, 2024	2,860,981		(5,000)
Stock-based compensation	$ 1	152,631			152,632
Stock-based compensation, shares	14,167
Net loss				(3,010,326)	(3,010,326)
Shares withheld to pay income taxes on stock-based compensation		(2,008)			(2,008)
Shares withheld to pay income taxes on stock-based compensation, shares	(1,265)
Balance at Jun. 30, 2024	$ 287	87,429,165	$ (300,000)	(81,105,788)	6,023,664
Balance. shares at Jun. 30, 2024	2,873,883		(5,000)
Stock-based compensation	$ 3	154,188			154,191
Stock-based compensation, shares	26,010
Shares issued in connection with capital raise, net of transaction costs	$ 37	931,254			931,291
Shares issued in connection with capital raise, net of transaction costs, shares	374,190
Net loss				(3,384,703)	(3,384,703)
Shares withheld to pay income taxes on stock-based compensation		(3,658)			(3,658)
Shares withheld to pay income taxes on stock-based compensation, shares	(2,139)
Balance at Sep. 30, 2024	$ 327	$ 88,510,949	$ (300,000)	$ (84,490,491)	$ 3,720,785
Balance. shares at Sep. 30, 2024	3,271,944		(5,000)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows From Operating Activities
Net loss	$ (9,121,410)	$ (8,716,589)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	481	82
Non-cash lease expense for right-of-use assets	64,700	60,552
Stock-based compensation	474,466	803,521
Warrants issued to purchase 158,007 shares of common stock in connection with a consulting agreement		1,310,875
Net changes in operating assets and liabilities:
Prepaid expenses and other	(1,020,375)	836,344
Operating lease liability	(61,776)	(57,929)
Accounts payable	400,093	18,751
Due (from) to related parties	(39)	5,740
Accrued expenses	266,539	(200,825)
Net cash used in operating activities	(8,997,321)	(5,939,478)
Cash Flows From Investing Activities
Purchase of property and equipment	(3,244)	(2,776)
Net cash used in investing activities	(3,244)	(2,776)
Cash Flows From Financing Activities
Net proceeds from common stock issued	7,213,721	6,352,077
Shares withheld to pay taxes on stock-based compensation	(15,590)
Settlement of stock award	(8,561)	(52,746)
Payment of finance lease obligation	(3,738)
Net cash provided by (used in) financing activities	7,185,832	6,299,331
Net Increase (Decrease) in Cash	(1,814,733)	357,077
Cash and Cash Equivalents – Beginning of Period	4,706,197	6,503,595
Cash and Cash Equivalents – End of Period	2,891,464	6,860,672
Non-Cash Financing Activities
Issuance of common stock in satisfaction of a due to licensor in connection with a licensing agreement	189,000
Right-of-use asset obtained in exchange for financing lease liability	11,804
Financing lease liability	(11,804)
Net

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	Sep. 30, 2023 shares
Consulting Agreement [Member] | Spartan Capital Securites LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants to purchase shares	158,007

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (3,384,703)	$ (3,010,326)	$ (2,726,381)	$ (2,081,951)	$ (2,612,565)	$ (4,022,073)	$ (9,121,410)	$ (8,716,589)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Note 1 – Organization and Summary of Significant Accounting Policies Organization We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts. On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended, with the Secretary of State of Delaware that effected a 1-for-20 reverse stock split 0.0001 24,706,474 1,291,000 24,606,474 1,286,000 100,000,000 Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. Liquidity Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $ 84.5 9.1 9.0 We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold 476,000 1,079,555 1,555,555 6.3 1,079,555 In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the “Registration Statement”), including a base prospectus relating to the offering of up to $ 50,000,000 2.4 931,000 374,190 We do not have sufficient cash on hand or available to fund our operations for the next twelve months. At September 30, 2024, we had cash and cash equivalents totaling $ 2.9 We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed. Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above. Use of Estimates In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows. Income Taxes We account for income taxes in accordance with ASC Topic 740, Income Taxes. Under ACS 740-270 Income Taxes – Interim Reporting Concentration of Credit Risk Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to specified limits. Total cash held by our banks at September 30, 2024, exceeded FDIC limits. Recent Accounting Pronouncements From time to time, the Financial Accounting Standards Board (“FASB”) or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (“ASU”). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ Equity	Note 2 – Stockholders’ Equity Preferred Stock There were no Common Stock During the nine months ended September 30, 2024, we sold 476,000 1,079,555 1,555,555 4.50 January 30, 2029 4.50 4.4999 0.0001 1,079,555 7.0 6.3 62,222 5.625 February 1, 2027 During the nine months ended September 30, 2024, we also received approximately $ 931,000 in net proceeds from the sale of 374,190 shares of common stock under the ATM Offering on July 31, 2024. During the nine months ended September 30, 2024, we also issued (i) 5,000 shares of common stock to Elion Oncology, Inc. (“Elion”) in satisfaction of the third milestone event under the license agreement; (ii) 30,000 shares of common stock to a consultant in accordance with their consulting agreement; and (iii) 16,199 shares of common stock to certain employees and consultants, net of 7,154 shares of common stock withheld for income taxes owed upon distribution of the shares.

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 3 - Stock-based Compensation On June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the “2019 Plan”). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of 800,000 353,641 Stock Compensation Expense We recorded stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 as follows: Schedule of Stock-based Compensation Expense 2024 2023 2024 2023 Three Months Ended Nine Months Ended 2024 2023 2024 2023 Research and development $ 54,018 $ 76,626 $ 130,722 $ 286,152 General and administrative 100,173 66,268 343,744 517,369 Total $ 154,191 $ 142,894 $ 474,466 $ 803,521 Stock Options Stock options to purchase 4,245 336.00 2,747 409.09 3.9 Restricted Stock Awards During the nine months ended September 30, 2024, we vested 1,250 9.26 no Restricted Stock Units Activity with respect to our Restricted Stock Units (“RSUs”) during the nine months ended September 30, 2024 was as follows: Schedule of Restricted Stock Units (“RSUs”) Activity Number of Weighted- average Outstanding at January 1, 2024 222,722 $ 45.82 Granted 192,026 1.63 Forfeited (13,750 ) 70.47 Issued (16,199 ) 109.35 Outstanding at September 30, 2024 384,799 20.21 Vested and unissued 144,450 44.89 Unvested at September 30, 2024 240,349 $ 5.38 On June 28, 2024, we granted RSUs for the future issuance of 39,202 14,969 18,173 3,030 3,030 On July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer (“CFO”). In addition to cash compensation, the Compensation Committee awarded RSUs for the future issuance of 28,000 14,000 7,000 30 7,000 15 On September 3, 2024, RSUs for the future issuance of 124,824 At September 30, 2024, unrecognized stock-based compensation expense of approximately $ 613,000 0.9 432,000 Holders of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights. Warrants During the nine months ended September 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase 1,617,777 7,500 15,000 10,000 At September 30, 2024, we had outstanding warrants for the purchase of 1,775,784 5.95 4.0

Net Loss per Share of Common St

Net Loss per Share of Common Stock	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss per Share of Common Stock	Note 4 – Net Loss per Share of Common Stock Net Loss Per Share Basic net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced a net loss for all periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and nine months ended September 30, 2024 and 2023 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive effect on net loss per share. The computation of net loss per share for the three and nine months ended September 30, 2024 and 2023 was as follows: Schedule of Net Loss Per Share Basic and Diluted 2024 2023 2024 2023 Three Months Ended Nine Months Ended 2024 2023 2024 2023 Basic and diluted net loss per share: Net loss available to common stockholders $ (3,384,703 ) $ (2,081,951 ) $ (9,121,410 ) $ (8,716,589 ) Weighted average number of common shares-basic and diluted 3,275,998 1,350,188 2,909,941 1,279,298 Basic and diluted net loss per share $ (1.03 ) $ (1.54 ) $ (3.13 ) $ (6.81 ) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Weighted-average number of common shares outstanding – basic and diluted 3,118,029 1,224,255 2,767,647 1,151,425 Weighted-average number of vested RSUs– basic and diluted 157,969 125,933 142,294 127,873 Weighted-average number of common shares-basic and diluted 3,275,998 1,350,188 2,909,941 1,279,298 Our diluted net loss per share for the three and nine months ended September 30, 2024 and 2023 excluded 2,018,880 289,936

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	Note 5 – Leases We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of 8 Lease costs included in our condensed consolidated statements of operations totaled approximately $ 23,000 24,000 68,000 73,000 Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases Remaining lease term (years) for our facility lease 1.0 Remaining lease term (years) for our equipment lease 1.4 Weighted average discount rate for our facility and equipment leases 8.0 % Annual lease liabilities for the operating lease were as follows at September 30, 2024: Schedule of Annual Lease Liabilities for all Operating Leases 2024 $ 23,347 2025 70,040 Total lease payments 93,387 Less: Interest (4,610 ) Present value of lease liabilities 88,777 Less: current maturities (88,777 ) Non-current lease liability $ - Annual lease liabilities for the financing lease were as follows at September 30, 2024: Schedule of Annual Lease Liabilities for all Financing Leases 2024 $ 1,616 2025 6,820 2026 488 Total lease payments 8,924 Less: Interest (857 ) Present value of lease liabilities 8,067 Less: current maturities (5,899 ) Non-current lease liability $ 2,168

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions CorLyst, LLC (“CorLyst”) reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated statement of operations. We recorded approximately $ 33,000 26,000 83,000 90,000 No

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Purchase Obligations We enter into contracts in the normal course of business with contract research organizations (“CROs”) and subcontractors to further develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and any applicable cancellation fees. At September 30, 2024, we are contractually committed to pay up to $ 13.0

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Organization	Organization We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts. On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended, with the Secretary of State of Delaware that effected a 1-for-20 reverse stock split 0.0001 24,706,474 1,291,000 24,606,474 1,286,000 100,000,000
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.
Liquidity	Liquidity Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of $ 84.5 9.1 9.0 We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold 476,000 1,079,555 1,555,555 6.3 1,079,555 In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the “Registration Statement”), including a base prospectus relating to the offering of up to $ 50,000,000 2.4 931,000 374,190 We do not have sufficient cash on hand or available to fund our operations for the next twelve months. At September 30, 2024, we had cash and cash equivalents totaling $ 2.9 We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed. Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.
Use of Estimates	Use of Estimates In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.
Income Taxes	Income Taxes We account for income taxes in accordance with ASC Topic 740, Income Taxes. Under ACS 740-270 Income Taxes – Interim Reporting
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to specified limits. Total cash held by our banks at September 30, 2024, exceeded FDIC limits.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, the Financial Accounting Standards Board (“FASB”) or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (“ASU”). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense	We recorded stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 as follows: Schedule of Stock-based Compensation Expense 2024 2023 2024 2023 Three Months Ended Nine Months Ended 2024 2023 2024 2023 Research and development $ 54,018 $ 76,626 $ 130,722 $ 286,152 General and administrative 100,173 66,268 343,744 517,369 Total $ 154,191 $ 142,894 $ 474,466 $ 803,521
Schedule of Restricted Stock Units (“RSUs”) Activity	Activity with respect to our Restricted Stock Units (“RSUs”) during the nine months ended September 30, 2024 was as follows: Schedule of Restricted Stock Units (“RSUs”) Activity Number of Weighted- average Outstanding at January 1, 2024 222,722 $ 45.82 Granted 192,026 1.63 Forfeited (13,750 ) 70.47 Issued (16,199 ) 109.35 Outstanding at September 30, 2024 384,799 20.21 Vested and unissued 144,450 44.89 Unvested at September 30, 2024 240,349 $ 5.38

Net Loss per Share of Common _2

Net Loss per Share of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share Basic and Diluted	The computation of net loss per share for the three and nine months ended September 30, 2024 and 2023 was as follows: Schedule of Net Loss Per Share Basic and Diluted 2024 2023 2024 2023 Three Months Ended Nine Months Ended 2024 2023 2024 2023 Basic and diluted net loss per share: Net loss available to common stockholders $ (3,384,703 ) $ (2,081,951 ) $ (9,121,410 ) $ (8,716,589 ) Weighted average number of common shares-basic and diluted 3,275,998 1,350,188 2,909,941 1,279,298 Basic and diluted net loss per share $ (1.03 ) $ (1.54 ) $ (3.13 ) $ (6.81 ) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Weighted-average number of common shares outstanding – basic and diluted 3,118,029 1,224,255 2,767,647 1,151,425 Weighted-average number of vested RSUs– basic and diluted 157,969 125,933 142,294 127,873 Weighted-average number of common shares-basic and diluted 3,275,998 1,350,188 2,909,941 1,279,298

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases	Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases Remaining lease term (years) for our facility lease 1.0 Remaining lease term (years) for our equipment lease 1.4 Weighted average discount rate for our facility and equipment leases 8.0 %
Schedule of Annual Lease Liabilities for all Operating Leases	Annual lease liabilities for the operating lease were as follows at September 30, 2024: Schedule of Annual Lease Liabilities for all Operating Leases 2024 $ 23,347 2025 70,040 Total lease payments 93,387 Less: Interest (4,610 ) Present value of lease liabilities 88,777 Less: current maturities (88,777 ) Non-current lease liability $ -
Schedule of Annual Lease Liabilities for all Financing Leases	Annual lease liabilities for the financing lease were as follows at September 30, 2024: Schedule of Annual Lease Liabilities for all Financing Leases 2024 $ 1,616 2025 6,820 2026 488 Total lease payments 8,924 Less: Interest (857 ) Present value of lease liabilities 8,067 Less: current maturities (5,899 ) Non-current lease liability $ 2,168

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)						3 Months Ended						9 Months Ended
	Jul. 31, 2024	May 31, 2024	May 21, 2024	Jan. 30, 2024	Jan. 22, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Jan. 21, 2024	Dec. 31, 2023
OrganizationLineItems [Line Items]
Reverse stock split					1-for-20 reverse stock split
Common stock, par value					$ 0.0001	$ 0.0001						$ 0.0001			$ 0.0001
Common stock shares issued					1,291,000	3,271,944						3,271,944		24,706,474	1,291,000
Common stock shares outstanding					1,286,000	3,266,944						3,266,944		24,606,474	1,286,000
Common stock shares authorized					100,000,000	100,000,000						100,000,000			100,000,000
Accumulated deficit						$ 84,490,491						$ 84,490,491			$ 75,369,081
Net loss						3,384,703	$ 3,010,326	$ 2,726,381	$ 2,081,951	$ 2,612,565	$ 4,022,073	9,121,410	$ 8,716,589
Net cash for operating activities from continuing operations												8,997,321	5,939,478
Net proceeds from sale of common stock				$ 6,300,000								7,213,721	$ 6,352,077
Cash and cash equivalents						$ 2,891,464						2,891,464			$ 4,706,197
ATM Offering [Member]
OrganizationLineItems [Line Items]
Shares issued	374,190
Net proceeds from sale of common stock	$ 931,000											$ 931,000
Registration Statement [Member] | Maximum [Member]
OrganizationLineItems [Line Items]
Maximum value to be sold		$ 50,000,000
Purchase Agreement [Member]
OrganizationLineItems [Line Items]
Shares issued				476,000								476,000
Net proceeds from sale of common stock												$ 6,300,000
Purchase Agreement [Member] | Warrant [Member]
OrganizationLineItems [Line Items]
Warrants to purchase shares				1,555,555		1,555,555						1,555,555
Purchase Agreement [Member] | Pre-Funded Warrants [Member]
OrganizationLineItems [Line Items]
Warrants to purchase shares				1,079,555		1,079,555						1,079,555
Warrant exercised				1,079,555		1,079,555						1,079,555
Sales Agreement [Member] | Maximum [Member] | Alliance Global Partners [Member] | ATM Offering [Member]
OrganizationLineItems [Line Items]
Maximum value to be sold at the market offering			$ 2,400,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)			9 Months Ended
	Jul. 31, 2024	Jan. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Class of Stock [Line Items]
Preferred stock, shares issued			0		0
Preferred stock, shares outstanding			0		0
Proceeds from Issuance of Common Stock		$ 6,300,000	$ 7,213,721	$ 6,352,077
Stock withheld for income taxes			7,154
Employees and Consultants [Member]
Class of Stock [Line Items]
Shares issued			16,199
ATM Offering [Member]
Class of Stock [Line Items]
Shares issued	374,190
Proceeds from Issuance of Common Stock	$ 931,000		$ 931,000
Purchase Agreement [Member]
Class of Stock [Line Items]
Shares issued		476,000	476,000
Gross proceeds from issuance of common stock			$ 7,000,000
Proceeds from Issuance of Common Stock			$ 6,300,000
Purchase Agreement [Member] | Placement Agent [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights			$ 5.625
Warrant expiration date			Feb. 01, 2027
Class of warrant or right, outstanding			62,222
Purchase Agreement [Member] | Warrant [Member]
Class of Stock [Line Items]
Class of warrant or right, number of securities called by warrants or rights		1,555,555	1,555,555
Class of warrant or right, exercise price of warrants or rights			$ 4.50
Warrant expiration date			Jan. 30, 2029
Purchase Agreement [Member] | Pre-Funded Warrants [Member]
Class of Stock [Line Items]
Class of warrant or right, number of securities called by warrants or rights		1,079,555	1,079,555
Class of warrant or right, exercise price of warrants or rights			$ 0.0001
Shares issued, price per share			$ 4.4999
Warrant exercised		1,079,555	1,079,555
License Agreement [Member] | Elion Oncology, Inc. [Member]
Class of Stock [Line Items]
Shares issued			5,000
Consulting Agreement [Member] | Consultant [Member]
Class of Stock [Line Items]
Shares issued			30,000

Schedule of Stock-based Compens

Schedule of Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 154,191	$ 142,894	$ 474,466	$ 803,521
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	54,018	76,626	130,722	286,152
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 100,173	$ 66,268	$ 343,744	$ 517,369

Schedule of Restricted Stock Un

Schedule of Restricted Stock Units (“RSUs”) Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, Beginning balance | shares	222,722
Weighted-average grant-date fair value per share, Beginning balance | $ / shares	$ 45.82
Number of shares, granted | shares	192,026
Weighted-average grant-date fair value per share, granted | $ / shares	$ 1.63
Number of shares, forfeited | shares	(13,750)
Weighted-average grant-date fair value per share, forfeited | $ / shares	$ 70.47
Number of shares, issued | shares	(16,199)
Weighted-average grant-date fair value per share, shares issued | $ / shares	$ 109.35
Number of shares, ending balance | shares	384,799
Weighted-average grant-date fair value per share, ending balance | $ / shares	$ 20.21
Number of shares, vested and unissued | shares	144,450
Weighted-average grant-date fair value per share, vested and unissued | $ / shares	$ 44.89
Number of shares, unvested | shares	240,349
Weighted-average grant-date fair value per share, unvested | $ / shares	$ 5.38

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($)				9 Months Ended
	Sep. 03, 2024	Jul. 16, 2024	Jun. 28, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payments for settlement of stock awards				$ 8,561	$ 52,746
Warrant [Member] | Offering [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase shares				1,617,777
Consulting Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants, expired				7,500
Share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures				15,000
Payments for settlement of stock awards				$ 10,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options, forfeited				4,245
Options, forfeited weighted average exercise price				$ 336
Options exercisable, shares				2,747
Options exercisable weighted average exercise price				$ 409.09
Exercisable weighted average remaining contractual term				3 years 10 months 24 days
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, vested				1,250
Weighted-average grant-date fair value per share, shares vested				$ 9.26
Number of shares, outstanding				0
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, outstanding				384,799		222,722
Number of shares, granted				192,026
Unrecognized share based compensation expense				$ 613,000
Weighted average period for recognition				10 months 24 days
Unrecognized share based compensation expense				$ 432,000
Restricted Stock Units (RSUs) [Member] | Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted			39,202
Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted		28,000
Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | July 16, 2025 Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted		14,000
Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | First Performance Based RSUs [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted		7,000
Market capitalization		$ 30,000,000
Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | Second Performance Based RSUs [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted		7,000
Performance vesting criteria		$ 15,000,000
Restricted Stock Units (RSUs) [Member] | Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted	124,824
Service Based RSUs [Member] | Employees [Member] | January 1, 2025 Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted			14,969
Service Based RSUs [Member] | Employees [Member] | 3-Year Vesting [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted			18,173
First Performance Based RSUs [Member] | Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted			3,030
Second Performance Based RSUs [Member] | Employees [Member] | Next Generation Capecitabine - Cap [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, granted			3,030
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants to purchase shares				1,775,784
Weighted average exercise price				$ 5.95
Weighted average remaining contractual life				4 years
2019 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum equity available for issuance			800,000
Shares available for future grants				353,641

Schedule of Net Loss Per Share

Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net loss available to common stockholders	$ (3,384,703)	$ (2,081,951)	$ (9,121,410)	$ (8,716,589)
Weighted average number of common shares-basic	3,275,998	1,350,188	2,909,941	1,279,298
Weighted average number of common shares-diluted	3,275,998	1,350,188	2,909,941	1,279,298
Basic net loss per share	$ (1.03)	$ (1.54)	$ (3.13)	$ (6.81)
Diluted net loss per share	$ (1.03)	$ (1.54)	$ (3.13)	$ (6.81)
Restricted Stock Units (RSUs) [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Weighted average number of common shares-basic	157,969	125,933	142,294	127,873
Weighted average number of common shares-diluted	157,969	125,933	142,294	127,873
Common Stock [Member]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Weighted average number of common shares-basic	3,118,029	1,224,255	2,767,647	1,151,425
Weighted average number of common shares-diluted	3,118,029	1,224,255	2,767,647	1,151,425

Net Loss per Share of Common _3

Net Loss per Share of Common Stock (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount	2,018,880	289,936	2,018,880	289,936

Schedule of Weighted Average Re

Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)	Sep. 30, 2024
Property, Plant and Equipment [Line Items]
Weighted average discount rate for our facility and equipment leases	8%
Facility Lease [Member]
Property, Plant and Equipment [Line Items]
Remaining lease term (years)	1 year
Equipment [Member]
Property, Plant and Equipment [Line Items]
Remaining lease term (years)	1 year 4 months 24 days

Schedule of Annual Lease Liabil

Schedule of Annual Lease Liabilities for all Operating Leases (Details)	Sep. 30, 2024 USD ($)
Leases
2024	$ 23,347
2025	70,040
Total lease payments	93,387
Less: Interest	(4,610)
Present value of lease liabilities	88,777
Less: current maturities	(88,777)
Non-current lease liability

Schedule of Annual Lease Liab_2

Schedule of Annual Lease Liabilities for all Financing Leases (Details)	Sep. 30, 2024 USD ($)
Leases
2024	$ 1,616
2025	6,820
2026	488
Total lease payments	8,924
Less: Interest	(857)
Present value of lease liabilities	8,067
Less: current maturities	(5,899)
Non-current lease liability	$ 2,168

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating and financing lease borrowing rate	8%		8%
Lease cost	$ 23,000	$ 24,000	$ 68,000	$ 73,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - CorLyst, LLC [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Related Party Transaction [Line Items]
Rent and other costs reimbursements received	$ 33,000	$ 26,000	$ 83,000	$ 90,000
Due from related parties	$ 0	$ 0	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Millions	Sep. 30, 2024 USD ($)
CROs [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase obligation	$ 13